Imprimis Pharmaceuticals Inc (IMMY.OQ)
Tue, Jan 30 2018
* IMPRIMIS PHARMACEUTICALS NOW MAKING AVAILABLE TWO GLAUCOMA DRUGS ON FDA'S DRUG SHORTAGE LIST Source text for Eikon: Further company coverage:
BRIEF-Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility
* IMPRIMIS PHARMACEUTICALS IS ISSUED DEA MANUFACTURER CERTIFICATE FOR ITS 503B OUTSOURCING FACILITY Source text for Eikon: Further company coverage:
Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.
* Imprimis Pharmaceuticals announces third quarter 2017 results
Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.
BRIEF-Imprimis Pharma CEO says company intends to start selling prescriptions for its cheaper alternative to Restasis on Nov 1
* CEO - Intends to start selling prescriptions for its cheaper alternative to Restasis on November 1 Further company coverage:
* Imprimis Pharmaceuticals-making compounded Cyclosporine-based formulations available for physicians to consider prescribing as alternatives to Restasis Source text for Eikon: Further company coverage:
* Imprimis Pharmaceuticals Inc - provided an update regarding FDA Medwatch notice issued on August 4, 2017
* Imprimis Pharmaceuticals Inc - responded to a press release issued by Allergan Plc regarding a lawsuit Allergan USA, Inc. filed against Imprimis
* Allergan files suits against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC
- Imprimis Pharmaceuticals' (IMMY) CEO Mark Baum on Q3 2017 Results - Earnings Call Transcript
- Mylan, Teva And Generic Delzicol Could Sting Allergan
- Imprimis To Challenge Allergan's Restasis With Cheaper Product
- Senator Seeks To Thwart Allergan's Patent Transfer
- Shire Sues Allergan In Dry-Eye Donnybrook
- Allergan: Is Imprimis Spat Another Ruse To Crush Restasis Competitor?